Insights
Search Results
Client Highlights
1.22.26
Wilson Sonsini Advises Janux Therapeutics on Patent Matters Related to License Agreement with Bristol Myers Squibb
On January 22, 2026, Janux Therapeutics (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), and Tumor Activated Immunomodulator (TRACIr) platforms, announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, the companies will develop a tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Wilson Sonsini Goodrich & Rosati advised Janux on patent matters related to the transaction.
Client Highlights
8.11.22
Wilson Sonsini Advises Marengo Therapeutics on Patent Matters Related to Strategic Partnership with Ipsen
On August 1, 2022, Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization. Under the terms of the agreement, Ipsen will make an upfront payment of $45 million, together with potential payments up to a total of $1.592 billion if all milestones are met in addition to tiered sales royalty payments. Marengo will lead the preclinical development efforts and will expense related costs until the submission of an Investigational New Drug (IND) application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization.
Client Highlights
6.24.22
Wilson Sonsini Advises CellPoint on Acquisition by Galapagos
On June 21, 2022, Galapagos, a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines, announced it has signed a definitive agreement for an all-cash acquisition of CellPoint for an upfront payment of €125 million, with additional milestone payments up to €100 million. CellPoint is dedicated to developing CAR-T therapies at the point-of-care, making these therapies more affordable and accessible to patients. Wilson Sonsini Goodrich & Rosati advised CellPoint on the transaction.
Client Highlights
6.25.21
Firm Advises Graphite Bio on IP Matters Related to Initial Public Offering
On June 24, 2021, Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced the pricing of its upsized initial public offering of 14,000,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Graphite Bio. The gross proceeds to Graphite Bio from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Graphite Bio, are expected to be $238.0 million. In addition, Graphite Bio has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
The Wilson Sonsini team that advised Graphite Bio on IP matters related to the transaction includes Lou Lieto, Clark Lin, Jason Nguyen, and Moonkyoung Um.
For more information, please see Graphite Bio’s press release.
The Wilson Sonsini team that advised Graphite Bio on IP matters related to the transaction includes Lou Lieto, Clark Lin, Jason Nguyen, and Moonkyoung Um.
For more information, please see Graphite Bio’s press release.
Client Highlights
6.17.21
Firm Advises Verve Therapeutics on IP Matters Related to $266.7 Million IPO
On June 16, 2021, Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced the pricing of its initial public offering of 14,035,789 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Verve from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $266.7 million. All of the shares are being offered by Verve. In addition, Verve has granted the underwriters a 30-day option to purchase up to an additional 2,105,368 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. The shares began trading on the Nasdaq Global Select Market on June 17, 2021, under the ticker symbol “VERV.” The offering is expected to close on June 21, 2021, subject to the satisfaction of customary closing conditions.